Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garry M Walsh

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Expert Review of Clinical Immunology|September 11, 2010
Targeting eosinophils in asthma: current and future state of cytokine- and chemokine-directed monoclonal therapyGarry M Walsh
Current Opinion in Otolaryngology & Head and Neck Surgery|February 25, 2017
Biologics for asthma and allergyGarry M Walsh
Therapeutics and Clinical Risk Management|May 14, 2008
[Not Available]Garry M Walsh
Biologics : Targets & Therapy|January 18, 2013
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthmaGarry M Walsh
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2013
Therapeutic potential of targeting interleukin 5 in asthmaGarry M Walsh
Therapeutics and Clinical Risk Management|October 2, 2008
[Not Available]Garry M Walsh
Expert Opinion on Emerging Drugs|February 2, 2012
An update on emerging drugs for asthmaGarry M Walsh
Expert Opinion on Emerging Drugs|May 30, 2015
Anti-IL-4/-13 based therapy in asthmaGarry M Walsh
Advances in Pharmacology (San Diego, Calif.)|July 31, 2023
Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatmentGarry M Walsh
Expert Opinion on Drug Safety|August 9, 2003
Emerging safety issues regarding long-term usage of H(1)receptor antagonistsGarry M Walsh
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Expert Review of Clinical Immunology|September 11, 2010
Targeting eosinophils in asthma: current and future state of cytokine- and chemokine-directed monoclonal therapyGarry M Walsh
Current Opinion in Otolaryngology & Head and Neck Surgery|February 25, 2017
Biologics for asthma and allergyGarry M Walsh
Therapeutics and Clinical Risk Management|May 14, 2008
[Not Available]Garry M Walsh
Biologics : Targets & Therapy|January 18, 2013
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthmaGarry M Walsh
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2013
Therapeutic potential of targeting interleukin 5 in asthmaGarry M Walsh
Therapeutics and Clinical Risk Management|October 2, 2008
[Not Available]Garry M Walsh
Expert Opinion on Emerging Drugs|February 2, 2012
An update on emerging drugs for asthmaGarry M Walsh
Expert Opinion on Emerging Drugs|May 30, 2015
Anti-IL-4/-13 based therapy in asthmaGarry M Walsh
Advances in Pharmacology (San Diego, Calif.)|July 31, 2023
Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatmentGarry M Walsh
Expert Opinion on Drug Safety|August 9, 2003
Emerging safety issues regarding long-term usage of H(1)receptor antagonistsGarry M Walsh
Pageof 6